Cellectar Biosciences, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CLRB Nasdaq 2830 www.cellectar.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cellectar Biosciences, Inc.

Is Cellectar Biosciences (CLRB) Stock Outpacing Its Medical Peers This Year? - Mar 18th, 2025 1:40 pm
Cellectar Biosciences Inc (CLRB) Q4 2024 Earnings Call Highlights: Strategic Restructuring and ... - Mar 14th, 2025 7:04 am
Q4 2024 Cellectar Biosciences Inc Earnings Call - Mar 14th, 2025 3:43 am
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update - Mar 13th, 2025 11:05 am
Cellectar Biosciences to Present at the 37th Annual Roth Conference - Mar 11th, 2025 12:05 pm
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025 - Mar 5th, 2025 1:05 pm
Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Feb 5th, 2025 1:05 pm
Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference - Jan 12th, 2025 11:00 pm
Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options - Dec 11th, 2024 4:25 pm
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring - Dec 10th, 2024 10:00 pm
Q3 2024 Cellectar Biosciences Inc Earnings Call - Nov 19th, 2024 6:39 am
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update - Nov 18th, 2024 12:05 pm
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225 - Nov 14th, 2024 1:05 pm
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer - Nov 12th, 2024 1:05 pm
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024 - Nov 11th, 2024 9:05 pm
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024 - Nov 7th, 2024 11:40 am
Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q - Nov 1st, 2024 9:00 pm
Cellectar Biosciences to Present at IWWM Featuring Iopofosine I 131 - Aug 30th, 2024 5:40 pm
Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom’s Macroglobulinemia - Aug 26th, 2024 10:40 am
Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq - Aug 23rd, 2024 9:00 pm